Apogee Therapeutics Inc APGE

$135.07 -0.01 (-0.01%)

Valuation

Market cap: 8,401,489,000
Revenue TTM: $0
Net income TTM: $-255,840,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 5,142,000
Avg volume: 1,808,356
Day's range: $135.06 – $135.09
Shares out: 62,201,000
Stochastic %K: 95%
Beta: 0.33
Analysts: Sell
Price target: $134.53

Price

Company profile

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 394-5230
Website: https://www.apogeetherapeutics.com
Address: One Letterman Drive, Building B Suites B6-850 and B6-800 The Presidio of San Francisco, San Francisco, United States

Latest news

No headlines yet.

Stocktwits

JFais Sep 26, 7:28 PM

From weekend discussions: $XBI - Trump at max pain (rising inflation & interest rates) with midterms approaching = Iran deal more likely? -Debate on investing in truly novel companies like $RVMD vs "me-betters" a la $APGE or $ORKA -Rebound trade in $PHAT, profitability in Q3

1 replies

TradeSun Sep 20, 6:29 PM

$ALT $APGE $FOLD $TECH It’s not only Tern regarding growing SI into a deal👇

3 replies

WhatsUpWhatsNot Sep 17, 4:08 PM

$APGE It’s events like today that motivate me to $BLIN more and more

0 replies

StockMarketToday247 Sep 2, 3:03 PM

$GOSS $CAMP $TRAW $APGE #Biotech #CapitalMarkets Clinical and regulatory catalysts are increasingly being written directly into financing structures. Recent deals tie later capital tranches to FDA acceptance, trial clearance, enrollment or clinical data. That creates a second layer of catalyst risk: success can raise asset value AND unlock runway. Failure can hit valuation AND remove expected capital. The screen I care about now: funded cash committed milestone capital optional warrant proceeds extra trigger conditions “Up to $100M” is not the same thing as $100M of liquidity. The better catalyst question: what happens to the balance sheet the morning after the result? That’s where we've got our eyes today. https://stockmarkettoday.beehiiv.com/p/biotech-catalysts-are-becoming-financing-events

1 replies

Mergerbrief Sep 2, 12:11 PM

$APGE / $ABBV expected to close today. No second request, no litigation, no activist, no drama. Announced, tendered, done. Not every deal needs a story. Some of them just pay you.

0 replies

STRelativeStrength Aug 31, 2:05 PM

$APGE undiscovered breakout with 459 watchers

0 replies

STRelativeStrength Aug 26, 5:36 PM

$APGE undiscovered breakout with 460 watchers

0 replies

TwongStocks Aug 26, 5:21 PM

$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.

0 replies